Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.

@article{Bali2004SuperiorAO,
  title={Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.},
  author={Purva Bali and Prince George and Pamela S Cohen and Jianguo Tao and Fei Yun Guo and Celia A. Sigua and Anasuya Vishvanath and Anna Scuto and Srinivas R Annavarapu and Warren Fiskus and Lynn C. Moscinski and Peter W Atadja and Kapil Bhalla},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 15},
  pages={4991-7}
}
PURPOSE Mutant FLT-3 receptor tyrosine kinase is a client protein of the molecular chaperone heat shock protein 90 and is commonly present and contributes to the leukemia phenotype in acute myelogenous leukemia (AML). LAQ824, a cinnamyl hydroxamate histone deacetylase inhibitor, is known to induce acetylation and inhibition of heat shock protein 90. Here, we determined the effects of LAQ824 and/or PKC412 (a FLT-3 kinase inhibitor) on the levels of mutant FLT-3 and its downstream signaling, as… CONTINUE READING
54 Extracted Citations
41 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 54 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…